DURECT

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DURECT reports robust revenue growth and advances AHFIRM trial

DURECT's financials improved notably in 2022, driven by milestone payments and revenue growth.
AHFIRM trial progress and potential of larsucosterol offer promising prospects for the company.
Balancing high R&D costs, regulatory milestones, and market competition are key challenges.
Strategic management of cash reserves and successful trial outcomes are critical for future success.

DURECT (DRRX) advances promising AH treatment with strong Q1 results

DURECT's Q1 performance reflects progress in the development of Larsucosterol for AH.
Strengths lie in positive clinical data, regulatory support, and market awareness.
Challenges include market recall, pricing strategy, and potential dosing issues.
Opportunities exist in market expansion, regulatory milestones, and cost-saving potential.

DURECT reports Q2 revenue, progresses AHFIRM trial, eyes oncology expansion

DURECT's Q2 2023 performance reflects a balance between revenue generation, strategic investments, and financial strengthening.
The company's strengths lie in advancing clinical trials, exploring new markets, and planning for commercial success.
Challenges include regulatory hurdles, financial sustainability, and addressing analyst inquiries, while opportunities abound in oncology expansion and market growth.
Overall, DURECT's focus on innovation, strategic partnerships, and market awareness positions it for future success and growth.

DURECT reports positive trial results for larsucosterol in AH

DURECT's financials and cash position remain stable, with a successful net proceeds raise and operational funding secured.
Larsucosterol's positive trial results and FDA Fast Track designation position it as a promising treatment for AH.
While challenges exist in regulatory pathways and trial complexities, the market potential for larsucosterol is substantial.
Overall, DURECT's focus on addressing AH with an effective treatment underscores its commitment to patient care.

DURECT reports revenue decline but positive trial results for larsucosterol

DURECT saw a decline in revenues but managed to reduce R&D and SG&A expenses in 2023.
Positive trial results and feedback position larsucosterol as a promising therapy for alcohol-associated hepatitis.
Navigating revenue challenges, regulatory discussions, and cost management are key focus areas for DURECT.

DURECT reports Q1 revenue dip, eyes FDA approval for AH treatment

DURECT's Q1 2024 performance saw revenue decline but cost management improvements.
Progress in larsucosterol Phase III trial and AHFIRM data acceptance signal positive developments.
While revenue challenges persist, opportunities in AH treatment market and financial stability are notable.
Strategic focus on AH patients' needs and efficient trial design position DURECT for future success.

DURECT reports revenue growth and progress in life-saving therapy trials

DURECT's Q2 2024 performance showed revenue growth and significant expense reductions.
Strengths lie in breakthrough therapy designation, positive study results, and cost-efficient trial planning.
Challenges include managing cash burn, meeting trial timelines, and industry competition.
Opportunities exist in market expansion, partnerships, pipeline diversification, and cost optimization.

DURECT reports improved Q3 financials and progresses key clinical trials

DURECT's financials improved in Q3 2024 with lower expenses and stable revenues, while advancing key clinical trials.
Despite challenges like licensing agreement termination, the company is poised for growth with promising trial results and strategic opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CUPERTINO, Calif., March 1, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients.

DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis

CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference call after the market close on Monday, March 7, 2022.

DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7

Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks

CUPERTINO, Calif., Jan. 6, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference

CUPERTINO, Calif. and ATHLONE, Ireland, Dec. 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, exclusive development and commercialization rights to POSIMIR® (bupivacaine solution) for infiltration use, DURECT's FDA-approved non-opioid, sustained-release local analgesic for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery, in the United States.

DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)

CUPERTINO, Calif., Dec. 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience.

DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia

CUPERTINO, Calif., Nov. 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced it will participate in a workshop today at the 5th Annual NASH Summit being held virtually from today through December 2, 2021.

DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit

CUPERTINO, Calif., Nov. 12, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of data at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting® 2021 showcasing an increase of hospitalizations for alcohol-associated hepatitis (AH) in the U.S. of approximately 19% (from 110,085 in 2015 to 131,510 in 2018) or approximately 4.8% per year between 2015 and 2018.

Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.

CUPERTINO, Calif., Nov. 10, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it dosed the first ex-U.S. patient in Australia as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis (AH) patients.

DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis

CUPERTINO, Calif., Nov. 8, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Suthat Liangpunsakul, M.D.

DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021

DURECT Corporation (DRRX) CEO Jim Brown on Q3 2021 Results - Earnings Call Transcript

CUPERTINO, Calif., Nov. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2021 and provided a corporate update.

DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs

CUPERTINO, Calif., Oct. 26, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the market close on Tuesday, November 2, 2021.

DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2

Durect (DRRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Durect (DRRX) Report Negative Q3 Earnings? What You Should Know

CUPERTINO, Calif., Oct. 7, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference

CUPERTINO, Calif., Sept. 23, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021

CUPERTINO, Calif., Sept. 15, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit

CUPERTINO, Calif., Sept. 7, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.

DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference

DURECT Corporation (DRRX) CEO Jim Brown on Q2 2021 Results - Earnings Call Transcript

CUPERTINO, Calif., July 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update.

DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs

CUPERTINO, Calif., July 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.

DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

CUPERTINO, Calif., July 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021.

DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit

CUPERTINO, Calif., June 23, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepatitis (NASH) and a Phase 1 trial in subjects with hepatic impairment (HI) as part of two posters at the 2021 International Liver Conference (EASL) being held virtually June 23-26, 2021.

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL)

Aeterna Zentaris

Amarin Corporation Plc

Globus Maritime

CarLotz

MediWound

Intec Parent

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 7 To Watch This Week

CUPERTINO, Calif., June 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL)  to be held virtually June 23-26, 2021.

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)

News for DURECT Stock (DRRX)